Ask anyone in pharma how long a drug patent lasts and they’ll say 20 years. The number is technically correct […]
Beyond 20 Years: What Actually Determines a Drug’s Market Exclusivity Read Post »
When a buyer writes a $74 billion check for a drugmaker, they are not paying for the molecule. They are
The Four Exclusivities Behind Every Pharma Mega-Deal Read Post »
Most pharmaceutical IP work gets framed as a pre-approval problem. File the composition patent during discovery, secure the use claims
Post-Approval Patents: The Hidden LOE Risk Map Read Post »
The most expensive number in pharmaceutical finance is the one nobody on the executive team wants to commit to: how
Patent Cliff Forecasting: How to Predict Drug Price Erosion Before It Happens Read Post »
Every time a pharmaceutical company changes something about an approved drug, it opens two doors simultaneously. The first leads to
The pharmaceutical industry has a math problem. A blockbuster drug throws off cash at a rate that makes any other
Pharma Patent Strategy: How to Defend Exclusivity Without Getting Sued Read Post »
A composition of matter patent is the only piece of pharmaceutical intellectual property that a generic or biosimilar manufacturer cannot
From Humira to Keytruda: The Blueprint for Surviving the Composition of Matter Cliff Read Post »
The composition-of-matter patent is the loudest piece of intellectual property a pharmaceutical company owns. It is also, increasingly, the least
Method-of-Use Patents: The Hidden Lever Rewriting Pharma’s Patent Cliff Math Read Post »
The Biologics Price Competition and Innovation Act turned fifteen years old in March, and the procedural ritual it created keeps
The Patent Dance Decoded: How Biosimilar Developers Win or Lose Before Litigation Starts Read Post »
Sign in or create a free account to read this DrugPatentWatch article
